10-Q: Kyverna Reports Wider Loss, Advances Cell Therapies

Kyverna Therapeutics reported increased net losses in Q2 2025 driven by higher R&D expenses, while making significant clinical progress with its lead cell therapy candidate KYV-101 for autoimmune diseases.

Summary

• Kyverna Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $42.1 million for the three months ended June 30, 2025, a 46% increase from $28.8 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $86.7 million, up 56% from $55.5 million in the prior year period.
• Research and development (R&D) expenses increased by 31% to $35.8 million for the three months ended June 30, 2025, and by 47% to $73.2 million for the six months ended June 30, 2025, primarily due to accelerated enrollment in KYSA trials and strategic investment in CMC for KYV-101.
• General and administrative (G&A) expenses rose by 41% to $8.6 million for the three months ended June 30, 2025, and by 43% to $18.6 million for the six months ended June 30, 2025, mainly due to increased personnel-related costs.
• Cash, cash equivalents, and available-for-sale marketable securities totaled $211.7 million as of June 30, 2025, down from $286.0 million at December 31, 2024.
• Management estimates existing cash resources are sufficient to fund operations for at least the next 12 months from the filing date, and into 2027.
• Patient enrollment for the KYV-101 pivotal Phase 2 trial in Stiff Person Syndrome (SPS) was completed in Q2 2025, with Phase 2 data expected in the first half of 2026.
• Patient enrollment for the KYV-101 Phase 2 trial in Myasthenia Gravis (MG) has been completed, with interim data expected in Q4 2025 and initiation of a Phase 3 portion by the end of 2025.
• Enrollment for KYV-101 Phase 1 trials in Lupus Nephritis (LN) has concluded, with data expected in a peer-reviewed publication in 2026.
• The company expects to file an Investigational New Drug (IND) application for KYV-102 in Q4 2025.
• Material weaknesses in internal control over financial reporting persist as of June 30, 2025, despite ongoing remediation efforts.
• The company is a defendant in a shareholder class action complaint and stockholder derivative complaints related to alleged misstatements/omissions in its IPO registration statement.

Sentiment

Score: 4

Explanation: The company shows strong clinical progress with key milestones met and upcoming data readouts, which is positive for a clinical-stage biotech. However, this is significantly overshadowed by rapidly increasing net losses and cash burn, coupled with persistent material weaknesses in internal controls and ongoing securities litigation. The financial health is deteriorating, and while the cash runway extends into 2027, it's heavily reliant on future capital raises. The overall sentiment is cautious due to high financial and operational risks despite clinical advancements.

Positives

• Completed patient enrollment for the pivotal Phase 2 trial (KYSA-8) of KYV-101 in Stiff Person Syndrome (SPS) during Q2 2025, with data expected in H1 2026.
• Completed patient enrollment for the Phase 2 trial (KYSA-6) of KYV-101 in Myasthenia Gravis (MG), with interim data anticipated in Q4 2025.
• Expanding the KYSA-6 trial to include a Phase 3 portion, with enrollment expected to begin by the end of 2025.
• Received Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA for KYV-101 in SPS (July 2024) and MG (August 2024).
• Received Orphan Drug Designations from the FDA for KYV-101 in MG (April 2024), SPS (August 2024), and SSc (September 2024), and from the European Medicines Association in MG.
• FDA confirmed the planned Chemistry, Manufacturing and Controls (CMC) package to support commercial manufacturing of KYV-101 for SPS and MG in March 2025.
• FDA accepted comparability data between two clinical manufacturing sites for KYV-101 in April 2025.
• Management estimates existing cash and marketable securities of $211.7 million are sufficient to fund operations for at least the next 12 months from the filing date, and into 2027.
• Filed a shelf registration statement on Form S-3 for up to $250.0 million, providing future capital raising flexibility.

Negatives

• Net loss significantly increased to $42.1 million for Q2 2025 from $28.8 million in Q2 2024, and to $86.7 million for the six months ended June 30, 2025, from $55.5 million in the prior year period.
• Research and development expenses increased substantially, reflecting higher CMO costs for CMC investment and CRO costs due to accelerated trial enrollment.
• General and administrative expenses also increased significantly due to higher personnel-related costs.
• Cash and cash equivalents and available-for-sale marketable securities decreased from $286.0 million at December 31, 2024, to $211.7 million at June 30, 2025.
• Net cash used in operating activities increased to $76.9 million for the six months ended June 30, 2025, from $49.7 million in the prior year period, indicating a high cash burn rate.
• Material weaknesses in internal control over financial reporting persist as of June 30, 2025, indicating ongoing control deficiencies.
• The company is involved in a shareholder class action lawsuit and stockholder derivative complaints alleging material misstatements or omissions in its IPO registration statement, which could incur significant costs and divert management attention.
• Interest income decreased by 50% for the three months and 30% for the six months ended June 30, 2025, primarily due to lower cash balances.

Risks

• The company has a limited operating history, has incurred substantial net losses since inception, and anticipates continued losses, with no products approved for commercial sale or revenue from product sales.
• Substantial additional capital will be required to finance operations; inability to raise funds could force delays or elimination of development programs.
• Business depends entirely on the success of product candidates, with no guarantee of successful development, regulatory approval, or commercialization.
• Results from investigator-initiated trials or named patient use are not representative of clinical trial performance and cannot be used for regulatory approval.
• Material weaknesses in internal control over financial reporting could lead to inaccurate or untimely financial reporting, adversely affecting investor confidence.
• Difficulties in managing organizational growth and expanding operations, or loss of key management/scientific personnel, could adversely affect the business.
• Preclinical and clinical development is lengthy, expensive, and uncertain, with earlier results not necessarily predictive of future trial outcomes.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Significant competition from large and specialty pharmaceutical/biotechnology companies, some with approved therapies in target indications.
• Use of product candidates could be associated with side effects, adverse events, or safety risks, potentially leading to trial suspension, delayed approval, or limited market acceptance.
• Reliance on third parties (CROs, CMOs, clinical sites) for preclinical studies, clinical trials, and manufacturing poses risks of non-performance, regulatory non-compliance, or supply disruptions.
• Dependence on intellectual property licensed from third parties; termination of licenses could result in loss of significant rights.
• Inability to obtain and maintain sufficient intellectual property protection could allow competitors to commercialize similar products.
• The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, with no assurance of obtaining approval.
• The FDA is investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed CAR T-cell immunotherapies (including KYV-101), which may impact regulatory review, delay approval, or require boxed warnings.
• Principal stockholders and management own a significant percentage of common stock, potentially controlling matters subject to stockholder approval.
• Unfavorable global economic conditions, including macroeconomic conditions or geopolitical events, could adversely affect the business.
• Risk of securities litigation, including the currently filed class action and derivative complaints, which are expensive and divert management attention.
• Stock price volatility and fluctuations in operating results may cause stock price to decline.
• The market opportunities for product candidates and market growth forecasts may not be accurate, potentially leading to smaller actual markets.
• Future issuance of equity or convertible debt securities would dilute share capital.
• Potential acquisitions, joint ventures, or investments could negatively affect operating results, dilute ownership, or increase debt.
• Changes in patent law in the United States and other jurisdictions could diminish the value of patents.
• Inability to protect the confidentiality of trade secrets would harm business and competitive position.
• Inadequate protection of trademarks and trade names could impede name recognition.
• Limited foreign intellectual property rights may hinder global protection.
• Failure to comply with environmental, health, and safety laws could result in fines or penalties.
• FDA and comparable foreign authorities may not accept data from clinical trials conducted outside the United States.
• Even if commercialized, products may be subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives.
• Disruptions at the FDA, SEC, and other government agencies (e.g., government shutdowns) could hinder their ability to perform normal business functions.
• The business may be impacted by actions of the current U.S. administration, including executive orders, policies, new legislation, and judicial decisions.
• Issues in the development and use of artificial intelligence, combined with an uncertain regulatory environment, may result in reputational harm or liability.

Future Outlook

Management estimates that existing cash, cash equivalents, and available-for-sale marketable securities of $211.7 million as of June 30, 2025, will be sufficient to fund planned operations and capital expenditure requirements for at least the next 12 months from the filing date, extending into 2027. The company expects to continue incurring substantial losses as it advances product candidates, expands its corporate infrastructure, and pursues regulatory approvals and potential commercialization. Future expenses are anticipated to increase significantly with ongoing clinical trials, manufacturing procurement, and intellectual property protection efforts. The company does not expect to generate revenue from product sales until successful development and regulatory approval of its candidates.

Management Comments

• Management estimates that existing cash and cash equivalents and available-for-sale marketable securities balances will be sufficient to fund the operating plan and capital expenditure requirements for at least the next 12 months from the filing date of this Quarterly Report on Form 10-Q, and into 2027.
• We expect that our cash, cash equivalents and available-for-sale marketable securities will allow us to support our first BLA filing for SPS, our registrational Phase 2/3 trial for MG and our pre-launch activities.
• We expect to continue to incur substantial losses for the foreseeable future, and our transition to profitability will depend upon the successful development, approval and commercialization of our product candidates and upon the receipt of sufficient revenues to support our cost structure.
• We do not expect to generate any revenue from commercial product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates.

Industry Context

The biopharmaceutical industry, particularly in cell therapies for autoimmune diseases, is highly competitive and capital-intensive. Kyverna Therapeutics operates in this environment, facing competition from large pharmaceutical and biotechnology companies with established products and significant resources. The company's focus on CAR T-cell therapy for autoimmune conditions like SPS, MG, and LN aligns with a growing area of interest in the industry, aiming for deep B cell depletion and durable remission. However, the field is also subject to evolving regulatory scrutiny, as evidenced by the FDA's investigation into T-cell malignancy risks associated with CAR T-cell immunotherapies, which could impact development and approval timelines across the sector.

Comparison to Industry Standards

• Kyverna's lead candidate, KYV-101, a CD19 CAR T-cell product, is designed with a fully human scFv domain, human CD8 hinge and transmembrane domain, human CD28 costimulatory domain, and human CD3 activation domain, which the company believes offers a differentiated therapeutic profile compared to other CAR T-cells.
• The underlying CAR in KYV-101 has completed a 20-patient Phase 1 trial in oncology by the NIH, with published results in Nature Medicine reporting similar rates of durable antitumor responses and improved tolerability compared to the CAR used to create Yescarta (a commercial CAR T-cell therapy by Kite Pharma, Inc.).
• In the autoimmune space, KYV-101 would compete with currently approved therapeutics such as Rituxan and Ocrevus (both from Roche Holding AG), and generic immunosuppressive or biosimilar drugs like mycophenolate mofetil, glucocorticoids, azathioprine, cyclophosphamide, and IVIG.
• Other product candidates in clinical development by third parties for B-cell-driven autoimmune diseases include obinutuzumab (targeting CD20 on B cells) from Genentech/Roche Holding AG.
• The company's strategy to achieve deep B cell depletion and durable drug-free, disease-free remission aims to present a significant advantage over current standard-of-care therapies, which often require continuous treatment.

Management Changes

Corporate Governance

Legal Proceedings

• A shareholder class action complaint was filed on December 9, 2024, in the United States District Court for the Northern District of California against the company, certain current and former officers and directors, and IPO underwriters. An amended complaint was filed on May 2, 2025, alleging material misstatements or omissions in the IPO registration statement on Form S-1 and prospectus. Defendants filed a motion to dismiss on June 26, 2025.
• Two stockholder derivative complaints (Perez v. Seidenberg, et al. filed May 14, 2025, and McDaniel v. Seidenberg, et al. filed May 22, 2025) were filed in the United States District Court for the Northern District of California against certain current and former officers and directors, alleging claims related to the class action. These derivative actions were consolidated on June 25, 2025, and stayed on July 22, 2025, pending the disposition of the motion to dismiss in the related securities class action.
• The company believes it has good and substantial defenses to these claims but is unable to determine whether any loss will occur or estimate the range of such loss; no amount of loss has been accrued in the financial statements as of June 30, 2025.

Related Party Transactions

• A $6.3 million sublicensing fee under the UCSF License Agreement (related to the Kite Agreement with Kite Pharma, Inc., an affiliate of Gilead Sciences, Inc.) was recorded as a current accrued license expense related party as of June 30, 2025, and December 31, 2024. No future milestones are payable to offset this fee due to the termination of the Gilead Agreement.
• On January 12, 2024, a promissory note of $1.1 million (principal and accrued interest) from the company's former Chief Executive Officer was forgiven. This was considered a repricing of options and a modification for accounting purposes.
• Severance payments of $0.4 million to the former Chief Executive Officer were recorded as other accrued expenses and current liabilities as of June 30, 2025, and December 31, 2024.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises, stock price volatility due to financial performance and litigation, and no anticipated dividends in the foreseeable future.
• Employees in research and development are increasing, with higher personnel-related expenses including stock-based compensation, but there is a risk of losing key management and scientific personnel.
• Patients stand to benefit from the development of cell therapies for severe autoimmune diseases, with ongoing clinical trials aiming for durable treatment-free remission, but also face risks of side effects and trial delays.
• Suppliers, Contract Manufacturing Organizations (CMOs), and Contract Research Organizations (CROs) are critical to the company's operations, but reliance on them introduces risks of supply chain disruptions, quality control issues, and compliance failures.
• Creditors may be impacted by the company's need for additional funding through debt financings, which could involve covenants limiting company actions.

Next Steps

• Report Phase 2 data from KYV-101 pivotal trial in Stiff Person Syndrome (KYSA-8) in the first half of 2026.
• Anticipate Biologics License Application (BLA) filing for KYV-101 in Stiff Person Syndrome (SPS) with the FDA in the first half of 2026.
• Report interim data from KYV-101 Phase 2 trial in Myasthenia Gravis (KYSA-6) in the fourth quarter of 2025.
• Initiate enrollment for the Phase 3 portion of KYV-101 trial in Myasthenia Gravis (KYSA-6) by the end of 2025.
• File an Investigational New Drug (IND) application for KYV-102 in the fourth quarter of 2025.
• Share data from KYV-101 Phase 1 trials in Lupus Nephritis (KYSA-1 and KYSA-3) in a peer-reviewed publication in 2026.
• Continue remediation efforts for identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

Kyverna Therapeutics is a clinical-stage biopharmaceutical company with promising cell therapy candidates for autoimmune diseases, evidenced by RMAT and Orphan Drug designations and progress in pivotal trials. However, the company is experiencing significant and increasing net losses and a high cash burn rate, which are concerning for its financial sustainability despite a stated cash runway into 2027. The ongoing material weaknesses in internal controls and active securities litigation add substantial operational and reputational risk. While clinical milestones provide long-term potential, the immediate financial and governance challenges warrant a cautious stance. A 'hold' recommendation reflects the balance between the high-risk, high-reward nature of biotech development and the current financial and operational headwinds.

Keywords

Biopharmaceutical, Cell Therapy, Autoimmune Disease, CAR T-cell, KYV-101, Stiff Person Syndrome, Myasthenia Gravis, Lupus Nephritis, Clinical Trials, SEC Filing, 10-Q, Drug Development, Biotech, Neuroimmunology, Rheumatology, Orphan Drug, RMAT, Manufacturing, Intellectual Property, Financial Reporting